|ISPOR Task Force on Good Research Practices--Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task …|
MC Weinstein, B O˘Brien, J Hornberger, J Jackson, M Johannesson, ...
Value Health 6 (1), 9-17, 2003
|The NICE cost-effectiveness threshold|
C McCabe, K Claxton, AJ Culyer
Pharmacoeconomics 26 (9), 733-744, 2008
|Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra|
K Claxton, M Sculpher, C McCabe, A Briggs, R Akehurst, M Buxton, ...
Health economics 14 (4), 339-347, 2005
|Whither trial‐based economic evaluation for health care decision making?|
MJ Sculpher, K Claxton, M Drummond, C McCabe
Health economics 15 (7), 677-687, 2006
|Patient volume, staffing, and workload in relation to risk-adjusted outcomes in a random stratified sample of UK neonatal intensive care units: a prospective evaluation|
UK Neonatal Staffing Study Group
The Lancet 359 (9301), 99-107, 2002
|Neonatal screening for inborn errors of metabolism: cost, yield and outcome.|
RJ Pollitt, A Green, CJ McCabe, A Booth, NJ Cooper, JV Leonard, ...
Health technology assessment (Winchester, England) 1 (7), i-iv, 1-202, 1997
|An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative …|
FJ Collinson, DG Jayne, A Pigazzi, C Tsang, JM Barrie, R Edlin, C Garbett, ...
International journal of colorectal disease 27 (2), 233-241, 2012
|Evaluation of a diabetic foot screening and protection programme|
CJ McCabe, RC Stevenson, AM Dolan
Diabetic Medicine 15 (1), 80-84, 1998
|Measuring the mental health status of a population: A comparison of the GHQ–12 and the SF–36 (MHI–5)|
CJ McCabe, KJ Thomas, JE Brazier, P Coleman
The British Journal of Psychiatry 169 (4), 517-521, 1996
|Orphan drugs and the NHS: should we value rarity?|
C McCabe, K Claxton, A Tsuchiya
Bmj 331 (7523), 1016-1019, 2005
|Value based pricing for NHS drugs: an opportunity not to be missed?|
K Claxton, A Briggs, MJ Buxton, AJ Culyer, C McCabe, S Walker, ...
Bmj 336 (7638), 251-254, 2008
|Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence|
A Culyer, C McCabe, A Briggs, K Claxton, M Buxton, R Akehurst, ...
Journal of health services research & policy 12 (1), 56-58, 2007
|Should patients have a greater role in valuing health states?|
J Brazier, R Akehurst, A Brennan, P Dolan, K Claxton, C McCabe, ...
Applied health economics and health policy 4 (4), 201-208, 2005
|Plantar foot pressures during treadmill walking with high-heel and low-heel shoes|
M Nyska, C McCabe, K Linge, L Klenerman
Foot & ankle international 17 (11), 662-666, 1996
|Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosisCommentary: Evaluating disease modifying treatments in …|
J Chilcott, DH Miller, C McCabe, P Tappenden, A O'Hagan, NJ Cooper, ...
Bmj 326 (7388), 522, 2003
|Funding the unfundable|
T Stafinski, CJ McCabe, D Menon
Pharmacoeconomics 28 (2), 113-142, 2010
|A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-á) inhibitors, adalimumab and infliximab, for Crohn's disease.|
J Dretzke, R Edlin, J Round, M Connock, C Hulme, J Czeczot, A Fry-Smith, ...
Health Technology Assessment (Winchester, England) 15 (6), 1, 2011
|Public healthcare resource allocation and the Rule of Rescue|
R Cookson, C McCabe, A Tsuchiya
Journal of medical ethics 34 (7), 540-544, 2008
|Using rank data to estimate health state utility models|
C McCabe, J Brazier, P Gilks, A Tsuchiya, J Roberts, A O˘Hagan, ...
Journal of health economics 25 (3), 418-431, 2006
|Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment|
DM Pickin, CJ McCabe, LE Ramsay, N Payne, IU Haq, WW Yeo, ...
Heart 82 (3), 325-332, 1999